Benefits of Lilly's diabetes candidate tirzepatide aren't better than other diabetes drugs, says watchdog ICER
Eli Lilly’s tirzepatide — the type 2 diabetes candidate and Trulicity’s heir apparent, projected to be a megablockbuster drug within the next five years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
